Phaseline

Targets › WRN

WRN (Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout May 2027.

Multifunctional enzyme that has magnesium and ATP-dependent 3'-5' DNA-helicase activity on partially duplex substrates. Also has 3'->5' exonuclease activity towards double-stranded (ds)DNA with a 5'-overhang. (UniProt, Q14191)

Open in Phaseline: the race on WRN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vividion TherapeuticsVVD-133214
WRN protein inhibitor
WRNPhase 2Colorectal Adenocarcinoma; Advanced Solid TumorsMay 2027
Eikon TherapeuticsEIK1005
Werner helicase inhibitor
WRNPhase 1Advanced Solid TumorsMar 2029
Nimbus WadjetNDI-219216
WRN helicase inhibitor
WRNPhase 1Advanced Solid Tumors CancerOct 2031

Conditions

Advanced Solid Tumors (2) Advanced Solid Tumors Cancer (1) Colorectal Adenocarcinoma (1)

Modalities

mixed (2), small molecule (1)

Companies

Nimbus Wadjet (1) Vividion Therapeutics (1) Eikon Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.